Prime Editing for Human Gene Therapy: Where Are We Now?

Area of Science:

• Molecular Biology
• Genetics
• Biotechnology

Background:

• Gene therapy aims to cure inherited diseases by targeting genetic mutations, unlike traditional symptom-treating medicines.
• CRISPR/Cas9 technology, discovered in 2012, revolutionized gene editing and paved the way for advanced therapeutic tools.
• Prime editing, developed from CRISPR/Cas9, enables precise DNA modifications, including insertions, deletions, and base conversions.

Purpose of the Study:

• To review the current state of prime editing technology for human gene therapy.
• To outline effective strategies for correcting pathogenic mutations using prime editing.
• To explore the potential of prime editing in treating a wide range of genetic disorders.

Main Methods:

• Review of scientific literature on prime editing technology and its applications.
• Analysis of preclinical studies demonstrating prime editing's efficacy in various disease models.
• Identification and discussion of strategies for precise gene correction via prime editing.

Main Results:

• Prime editing has shown promise in preclinical studies for liver, eye, skin, muscular, and neurodegenerative diseases.
• Applications include treatments for cystic fibrosis, beta-thalassemia, X-linked severe combined immunodeficiency, and cancer.
• The technology allows for targeted insertions, deletions, and all 12 base-to-base conversions in the human genome.

Conclusions:

• Prime editing represents a significant advancement in gene therapy, offering precise correction of genetic defects.
• Ongoing research and development are expanding its therapeutic potential for numerous inherited diseases.
• Strategic application of prime editing holds promise for developing curative treatments for genetic conditions.